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Background:  Doctor-shopping  (obtaining  prescriptions  from  multiple  prescribers/pharmacies)  for  opioid
analgesics  produces  a supply  for diversion  and  abuse,  and  represents  a major  public health  issue.
Methods:  An open  cohort  study  assessed  changes  in  doctor-shopping  in  the  U.S.  for a brand  extended
release  (ER)  oxycodone  product  (OxyContin)  and comparator  opioids  before  (July,  2009  to June,  2010)
versus  after  (January,  2011  to June,  2013)  introduction  of  reformulated  brand  ER  oxycodone  with  abuse-
deterrent properties,  using  IMS  LRx  longitudinal  data  covering  >150  million  patients  and  65% of  retail
U.S.  prescriptions.
Results:  After  its  reformulation,  the  rate of doctor-shopping  decreased  50%  (for  2+ prescribers/3+  phar-
macies)  for  brand  ER oxycodone,  but not  for comparators.  The  largest  decreases  in rates  occurred  among
young  adults  (73%),  those  paying  with  cash  (61%)  and  those  receiving  the  highest  available  dose  (62%),
with  a 90%  decrease  when  stratifying  by  all three  characteristics.  The  magnitude  of  doctor-shopping
reductions  increased  with  increasing  number  of prescribers/pharmacies  (e.g., 75%  reduction  for  ≥2
prescribers/≥4  pharmacies).
Conclusions:  The  rate  of doctor-shopping  for brand ER oxycodone  decreased  substantially  after  its  refor-
mulation,  which  did  not  occur  for other  prescription  opioids.  The  largest  reductions  in doctor-shopping
occurred  with  characteristics  associated  with  higher  abuse  risk  such  as youth,  cash  payment  and  high
dose,  and with  more  speciﬁc  thresholds  of  doctor-shopping.  A  higher  prescriber  and/or  pharmacy  thresh-
old also  increased  the  magnitude  of  the  decrease,  suggesting  that  it better  captured  the  effect  of the
reformulation  on  actual  doctor-shoppers.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Background
Opioid analgesics are an important option for the treatment of
ain, but their abuse and diversion are a major concern. Physicians
nd other prescribers are a primary source of opioids for abuse
Hall et al., 2008; McLellan and Turner, 2008; Shepherd, 2014),
ither unknowingly to those purporting to be patients or know-
ngly providing prescriptions that are diverted such as through
pill mills” (illegal practices focused on prescribing and dispens-
ng large quantities of opioids). A means by which individuals can
btain drugs for abuse and diversion is doctor-shopping, which is
he practice of engaging multiple prescribers and/or pharmacies
o obtain excess drug that can be diverted for non-medical use.
∗ Corresponding author at: Purdue Pharma L.P., Stamford, CT, United States.
E-mail address: paul.coplan@pharma.com (P.M. Coplan).
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.06.009
376-8716/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Although the proportion of patients prescribed opioids who doctor-
shop appears to be relatively small (Cepeda et al., 2012; McDonald
and Carlson, 2013), doctor-shoppers account for a disproportion-
ately high share of opioid prescriptions. Given the large number of
opioid prescriptions each year (with hydrocodone being the most
highly prescribed drug in the U.S.; IMS  Health, 2012), prescriptions
obtained through doctor-shopping impose a burden on prescribers,
who must determine if patients are seeking opioids for non-medical
purposes. It is also problematic for pain patients who need opi-
oid treatment, but may  be hesitant to introduce the potential for
mistrust in their patient-doctor relationship by seeking an opioid
prescription. Therefore, it is important to understand indicators of
doctor-shopping behavior and search for ways to minimize this
practice.One approach that has potential to reduce demand for a pre-
scription opioid for abuse is the development of opioids with
abuse-deterrent properties (Alexander et al., 2014; Bannwarth,
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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012; Lourenco et al., 2013; Michna et al., 2014; Pergolizzi and
eQuang, 2014). We  hypothesized that opioid formulations that
re effective in deterring abuse would reduce diversion, including
hrough doctor-shopping.
This report tests this hypothesis by estimating changes in rates
f doctor-shopping in the periods before versus after the introduc-
ion of a reformulation of brand ER oxycodone product in the U.S.
he original formulation of this product could be readily manipu-
ated for abuse by chewing, crushing (for snorting or smoking) or
y dissolving in solution (for injecting). Brand ER oxycodone was
eformulated with a physicochemical barrier to breaking, crushing
r dissolving and was approved by the FDA in April 2010. Starting
n August 2010, shipments for original brand ER oxycodone in the
.S. ceased and shipments for reformulated brand ER oxycodone
egan. By early 2011 nearly all brand ER oxycodone dispensed
as the reformulated product and there were few prescriptions
f generic ER oxycodone. The rapid switch from original to refor-
ulated brand ER oxycodone provides an opportunity to estimate
ts impact on its diversion. Clinical abuse studies demonstrated
educed abuse liability of brand ER oxycodone (Harris et al., 2014;
errino et al., 2013). FDA awarded labeling in 2013 that the product
as expected to deter abuse by the nasal and intravenous routes.
pidemiologic studies have shown reductions in abuse and diver-
ion of reformulated brand ER oxycodone in the community in the
.S. (Butler et al., 2013; Cicero et al., 2012; Coplan et al., 2013;
avens et al., 2014; Sessler et al., 2014; Severtson et al., 2013) and
ustralia (Degenhardt et al., 2015).
In this study, an established methodology to measure doctor-
hopping in the U.S. was utilized that takes into account
verlapping prescriptions from multiple prescribers and pharma-
ies (Cepeda et al., 2012) to compare rates of doctor-shopping
f brand ER oxycodone and other opioid products in the peri-
ds before versus after the introduction of reformulated brand
R oxycodone. Although prior research suggests useful cut-offs
or numbers of prescribers and pharmacies, there is no accepted
hreshold to deﬁne doctor-shopping. However, it was expected that
f the reformulation of brand ER oxycodone resulted in a reduc-
ion in doctor-shopping it would be more evident as the threshold
ncreased from a more sensitive cutoff (e.g., requiring overlapping
rescriptions from one or two prescribers or pharmacies) versus a
hreshold with higher speciﬁcity requiring larger numbers of pre-
cribers and/or pharmacies. Doctor-shopping deﬁnitions using low
hresholds are more likely to include individuals who  are not actu-
lly doctor-shoppers but obtained their prescriptions from multiple
rescribers or pharmacies for legitimate reasons, e.g., living in mul-
iple states during different seasons. These individuals would not
e included when the doctor-shopping thresholds were increased
o require more prescribers and/or pharmacies. Further, increas-
ng the speciﬁcity of doctor-shopping to include characteristics
ssociated with abuse and diversion such as younger age, cash pay-
ent and high dosage strength (Cepeda et al., 2012, 2013; Wilsey
t al., 2010, 2011) would be expected to result in larger declines in
octor-shopping following the introduction of reformulated brand
R oxycodone if an abuse-deterrent formulation affected its diver-
ion rate, using doctor-shopping as a proxy indicator of the actual
iversion rate.
Following the introduction of reformulated ER oxycodone in
010, there were several interventions that could have affected
iversion of opioids in general. For example, in 2011 there were
rackdowns on “pill mills” in Florida which were sources of large
uantities of opioids for diversion. The ER/LA Opioid Risk Evalua-
ion and Mitigation Stategy (Class REMS) went into effect in 2012. In
ddition, use of prescription monitoring programs (PMPs) became
ore widespread and expanded to 49 states. In order to determine
hether reductions in doctor-shopping were speciﬁc to brand ER
xycodone and not seen for other prescription opioid products asependence 165 (2016) 221–228
a result of these interventions, changes in rates of doctor-shopping
were estimated for comparator opioids.
A reformulation of brand ER oxymorphone (Opana® ER) was
introduced in early 2012. The manufacturer reformulated with the
intent to impart abuse deterrent properties, but the FDA did not
award abuse deterrent labeling to the product. However, declines
in abuse of brand ER oxymorphone have been observed (RADARS
System, 2013). This provided a unique opportunity to observe
trends in rates of doctor-shopping in two  reformulated products
that were both intended to confer abuse deterrent properties
and were introduced at different times. The goal was to use a
quasi-experimental approach to shed light on whether opioids
with intended abuse-deterrent properties might reduce doctor-
shopping and thereby reduce the burden on prescribers confronted
with patients seeking opioids for the purpose of abuse and diver-
sion.
2. Methods
The IMS  LRx database covers approximately 65% of all retail
prescriptions ﬁlled in the U.S. and uses de-identiﬁed data with a
unique encrypted ID that enables multiple prescriptions dispensed
to a patient to be linked over time. Over 150 million unique patients
are included in this longitudinal database, which contains prescrip-
tions from over one million prescribers. Unprojected longitudinal
patient-level data were used in this analysis.
Using these data, doctor-shopping rates were estimated for
six-month calendar intervals (i.e., January–June, July–December)
before and after the introduction of reformulated brand ER oxy-
codone. The pre-formulation period spanned from July, 2009 to
June, 2010, a transition period spanned from July to December,
2010, and the post-reformulation period spanned from January,
2011 to June, 2013.
For each six-month calendar period, overlaps in prescriptions
for speciﬁc opioid products were identiﬁed based on the start date
and the number of days of supply of each prescription. At least one
day of overlap was  required to be considered an overlap event. For
each overlap event the number of unique prescribers and pharma-
cies were counted. We  chose a minimum of 0 and a maximum of 5
prescribers or pharmacies, and translated the number of patients
that met  the threshold for doctor-shopping using all permutations
of this range of prescribers and/or pharmacies.
All combinations of prescriber and pharmacy quantities were
examined for changes in shopping rates pre- versus post-
reformulation of brand ER oxycodone. Initial analyses were
conducted using a cut-off of at least two unique prescribers and
three unique pharmacies, which was  based on published results
(Cepeda et al., 2012). For each six-month period, the doctor-
shopping rate was estimated by the number of individuals meeting
the threshold for shopping divided by the number of individu-
als with a prescription for that product in the six-month period.
Doctor-shopping rates were estimated separately for each product;
consequently, an individual could be counted as doctor-shopper for
more than one product. The average doctor-shopping rates were
estimated across the two  6-months periods in the one year pre-
reformulation period and across the ﬁve 6-month periods in the
2.5 years after reformulation (post-period). In order to measure
change in doctor-shopping rates from the pre- to the post-period,
the relative risk (ratepre/ratepost) and 95% conﬁdence intervals were
estimated for brand ER oxycodone and comparator opioids. In addi-
tion, to estimate differences in changes in rates of doctor-shopping
for brand ER oxycodone vs. comparators, the ratio of relative risks
was estimated for brand ER oxycodone relative to each compara-
tor, RRERoxycodone/RRcomparator (Altman and Bland, 2003). If the ratio
of relative risks <1 then the decline in rates for brand ER oxy-
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Table  1
Changes in doctor-shopping rates for brand ER oxycodone relative to changes for comparator opioid analgesics and benzodiazepines pre- and post-reformulation of brand
ER  oxycodone.
Product Total number of
patients
Pre-period
(3Q09–2Q10)a
Total number of
patients
Post-period
(1Q11–2Q13)a
Pre-period Rate
(3Q09–2Q10)
Post-period Rate
(1Q11–2Q13)
Pre-to-Post %
Change (95% CI)
Relative
Risk
Ratio of Relative
Risk (95% CI)
ER oxycodone (brand) 849,860 2,130,955 0.25% 0.12% −50 (−53, −47) 0.49 –
IR  hydromorphone 620,444 1,949,226 0.09% 0.06% −25 (−31, −17) 0.75 0.66 (0.59, 0.74)
IR  oxycodone APAP 9,335,562 25,167,863 0.13% 0.10% −23 (−25, −21) 0.77 0.65 (0.61, 0.69)
IR  hydrocodone APAP 26,479,737 74,140,839 0.15% 0.13% −13 (−14, −12) 0.87 0.58 (0.54, 0.61)
benzodiazepines 15,519,660 43,160,231 0.18% 0.16% −9 (−10, −7) 0.91 0.55 (0.51, 0.58)
ER  Morphine 663,514 2,164,569 0.09% 0.09% 4 (−5, 14) 1.04 0.48 (0.43, 0.53)
IR  oxycodone SE 1,527,554 6,420,004 0.34% 0.36% 5 (2, 9) 1.05 0.47 (0.44, 0.51)
ER  oxymorphone 103,559 400,809 0.09% 0.15% 66 (34, 106) 1.66 0.30 (0.24, 0.37)
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iource:IMS.
ata 3Q/4Q 2010 was considered a transition period.
a Pre-period encompasses a one-year period and post-period includes 2.5 years.
odone was of larger magnitude than declines for comparators.
hese comparators included immediate release (IR) oxycodone
ingle-entity (SE), IR hydromorphone, ER oxymorphone, and ER
orphine, as well as combination opioid products including IR
xycodone/acetaminophen and IR hydrocodone/acetaminophen.
enzodiazepines also were used as a comparator group. Because
f the small number of prescriptions (less than 1000 per month
y 2012), generic ER oxycodone was not used as comparator in
his study. ER oxymorphone included brand product as well as
mall numbers of generic product without abuse deterrent features
ntroduced in late 2011.
Because risk of abuse and diversion varies by age, rates of doctor-
hopping were stratiﬁed by age group. In addition, doctor-shopping
ates were estimated for overlapping prescriptions that included
t least one prescription paid with cash and/or for higher dosage
trength of brand ER oxycodone (80 mg  tablets), characteristics that
re also associated with abuse and diversion.
. Results
Doctor-shopping rates were initially estimated using a pre-
peciﬁed cutoff of at least two unique prescribers and three unique
harmacies during overlap events. For brand ER oxycodone, in
he one year pre-reformulation period, there were 2087 patients
ho reached this threshold out of a total of 849,860 patients
ho had at least one prescription of that product resulting in
n average doctor-shopping rate of 0.25% during that period. In
he 2.5 year post-reformulation period, there were 2606 out of
,130,955 patients prescribed brand ER oxycodone who  reached
his threshold (average doctor-shopping rate = 0.12%). Hence, there
as a 50% decrease in the average doctor-shopping rate of brand ER
xycodone from pre- to post-reformulation (95% CI = −53% to −47%,
able 1). Table 1 also shows changes in average doctor-shopping
ates for seven comparators from the pre- to post-reformulation
eriods. Among the comparators, changes ranged from an average
5% decrease for IR hydromorphone to an average 66% increase for
R oxymorphone. IR oxycodone SE had the highest rate of doctor-
hopping in the pre-reformulation period and it did not show a
hange in average rate over time. The magnitude of the reduc-
ion in doctor-shopping rate for brand ER oxycodone exceeded that
f each comparator as indicated by estimates of ratio of relative
isk <1 (with upper bounds of 95% conﬁdence intervals well below
), which showed that the decrease for brand ER oxycodone was
reater than observed for any of the comparators.
Age-speciﬁc doctor-shopping rates for brand ER oxycodone and
he comparators were estimated as the percent of patients who
octor-shop out of total patients prescribed a speciﬁed product
n a speciﬁed age group in the pre- and post-reformulation peri-ods (Fig. 1). In the pre-reformulation period, for SE opioids (brand
ER oxycodone, IR oxycodone SE, ER oxymorphone and ER mor-
phine) there was  a similar age-speciﬁc pattern in which young
adults (18–29 years old) had the highest rates of doctor-shopping,
with rates that were lower for increasing ages. This age-dependent
distribution of doctor-shopping for SE drugs was different from
that seen for combination products or benzodiazepine for which
the highest prevalence in both the pre-and post- periods was
seen in the 30–44 and 45–54 year age groups. Fig. 1A shows
that among patients prescribed brand ER oxycodone, very large
decreases in doctor-shopping (73%) occurred among young adults
(18–29 years). Large decreases also occurred in the age groups
30–44 and 45–54 years (51% and 46%, respectively). The two old-
est age groups (55–64 and 65+ years) had the lowest rates of
brand ER oxycodone doctor-shopping in the pre-period. Relative
to younger age groups, these age groups had small decreases in
rates of doctor-shopping (25% and 29%, respectively). In contrast
to these observations, the comparators had modest decreases at
most and in some cases large increases in doctor-shopping rates
post- versus pre-reformulation. In summary, pre-reformulation the
brand ER oxycodone age-speciﬁc doctor-shopping pattern with
highest rates in young adults was similar to other SE opioid prod-
ucts, whereas post-reformulation the age-speciﬁc pattern for brand
ER oxycodone was similar to those of opioid/acetaminophen com-
bination products with higher rates in older adults.
In addition to age, we examined two additional characteristics
that have been shown to be associated with abuse and diversion,
ie, cash payment and high dosage strength (Cepeda et al., 2013;
McDonald and Carlson, 2013; Degenhardt et al., 2015). Using the
previous threshold (2+ prescribers/3+ pharmacies) and requiring
at least one overlapping prescription to be paid with cash, there
was a 61% decrease in doctor-shopping for brand ER oxycodone
(Fig. 2A). When at least one of the overlapping prescriptions was
for the highest available brand ER oxycodone dosage strength
(80 mg), doctor-shopping decreased 62%. For overlap events involv-
ing both a cash payment and 80 mg  dosage strength, there was
a 70% decrease in brand ER oxycodone doctor-shopping. Hence,
increasing the speciﬁcity of the doctor-shopping deﬁnition resulted
in a larger decrease than the 50% decrease for all payment types
and dosage strengths. As the largest decrease in brand ER oxy-
codone doctor-shopping among all age subsets was seen in young
adults (73%, Fig. 2), changes in doctor-shopping for this age-group
for a cash payment and/or high dosage strength was  examined.
There was an 81% decrease in brand ER oxycodone doctor-shopping
involving a cash payment, an 86% decrease involving 80 mg  dosage
strength and a 90% decrease in brand ER oxycodone doctor-
shopping involving both a cash payment and 80 mg dosage strength
in young adults (Fig. 2B).
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Fig. 1. Changes in doctor-shopping rates (based on overlapping prescriptions with ≥2 prescribers and ≥3 pharmacies in 6 month periods) by age group for opioid analgesics
and  benzodiazepines. The values at the top of the bars indicate the percent change in the post- versus the pre-reformulation period for each age group. Before = July to
December 2010, After = January 2011 to June 2013.
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Fig. 2. Changes in doctor-shopping rates for brand ER oxycodone stratiﬁed by cash
payment and high dosage strength tablets (based on overlapping prescriptions with
≥
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ars indicate the percent change in the post- versus the pre-reformulation period for
ach age group. Before = July to December 2010, After = January 2011 to June 2013.
As shown in Fig. 3, the decrease in doctor-shopping rates
pre- vs. post- reformulation) using a higher threshold for doctor-
hopping (2+ prescribers and 4+ pharmacies) was  75% versus 50%
stimated using a lower threshold (2+ prescribers and 3+ pharma-
ies, the standard for the study). Once a threshold of four prescribers
r pharmacies was reached, the magnitude of the doctor-shopping
ecrease pre- versus post-reformulation stabilized (tallying addi-
ional prescribers/pharmacies had little effect).
ig. 3. Changes in rates of doctor-shopping for brand ER oxycodone from before (July to D
f  prescribers and pharmacies used to obtain prescriptions during periods of overlappin
ost-reformulation).ependence 165 (2016) 221–228 225
To further explore whether the declines in doctor-shopping
rates for brand ER oxycodone could be attributed to its abuse deter-
rent properties rather than interventions affecting opioids more
generally, age-speciﬁc trends for brand ER oxycodone were com-
pared to those for ER oxymorphone. As shown in Fig. 4a, there
were declines in doctor-shopping for brand ER oxycodone and ER
oxymorphone that were temporally linked to the introduction of
each respective formulation. Further, similar age-speciﬁc trends
were observed for both products (Fig. 4b) in which highest ini-
tial pre-reformulation rates and largest declines were observed for
younger individuals. Note that declines in ER oxymorphone doctor-
shopping were observed despite some availability of generic
products without abuse deterrent features, which would have been
expected to be a more likely target of doctor-shopping than the
reformulated product.
4. Discussion
The results from this study show that the rate of doctor-
shopping for an opioid product decreased markedly after its
reformulation with abuse-deterrent properties. Decreases in rates
of doctor-shopping were greater among patients with characteris-
tics associated with abuse and diversion including larger decreases
for young adults than other age groups, for those paying at least
once by cash, and for higher strength tablets. There was a 90%
decrease in brand ER oxycodone doctor-shopping from before to
after reformulation among 18–29 year olds paying with cash and
obtaining 80 mg  strength tablets. In addition, decreases in rates
of brand ER oxycodone doctor-shopping were greater for doctor-
shopping thresholds requiring a greater number of prescribers and
pharmacies.
While there were declines in rates of doctor-shopping for some
other opioid products, there was  a more pronounced decrease
for brand ER oxycodone. This pattern of ﬁndings suggests that
interventions such as increased use of PMPs and increased law
enforcement have had an impact on doctor-shopping in general,
and that the abuse deterrent properties of brand ER oxycodone con-
tributed to independent declines. Findings that there were declines
in doctor-shopping for ER oxymorphone after its reformulation are
similar to those for brand ER oxycodone provide further support
for an independent effect of intended abuse-deterrent properties
on doctor-shopping.
ecember 2010) versus after (January 2011 to June 2013) reformulation, by number
g prescriptions (Darker cell shading indicates larger changes in rates from pre- to
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aFig. 4. Trends in rates of doctor-shopping for brand ER oxycodone and ER
Findings in this report extend previous ﬁndings that have
emonstrated reductions in abuse and diversion of brand ER oxy-
odone after its reformulation with abuse-deterrent properties.
peciﬁcally, these studies found reductions in abuse in several dif-
erent populations including exposures reported to Poison Centers
Coplan et al., 2013; Severtson et al., 2013), individuals assessed
n substance abuse treatment (Butler et al., 2013; Cicero et al.,
012; Dart et al., 2015) and at supervised injection centers in
ustralia (Degenhardt et al., 2015), brand ER oxycodone abusers
n rural Kentucky (Buer et al., 2014; Havens et al., 2014) and fatal-
ties reported to the manufacturer (Sessler et al., 2014). Severtson
t al. (2013) showed reductions in diversion events involving brand
R oxycodone, (including arrests and seizures) reported by law
nforcement personnel. This study provides evidence that abuse-
eterrent formulations can also reduce diversion in the form of
octor-shopping.
Single-entity (SE) opioid products are more likely to be abused
hrough non-oral routes (injecting and snorting) than combina-
ion products (Butler et al., 2011) among individuals entering
ubstance abuse treatment. For example, SE oxycodone is often
bused through non-oral routes; 65% and 21% of individuals
ssessed in substance abuse treatment who report abuse of SEorphone for the periods before and after reformulation of each product.
oxycodone in the past 30 days reported abuse via snorting and
injecting routes, respectively (Butler et al., 2011). Furthermore, in
the pre-reformulation period, young adults had a higher preva-
lence of non-medical use of brand ER oxycodone than other opioid
pain relievers (Martins et al., 2009). In a sample of individu-
als assessed in substance abuse treatment (Cicero et al., 2013),
it was  found that young adults were more likely to abuse oxy-
codone than older adults. In contrast, hydrocodone combination
opioid products were preferred by older adults and were used
mostly by oral routes (95% oral, 27% snorting and 4% inject-
ing). After its reformulation, there was a shift in the shape of
the age-speciﬁc doctor-shopping proﬁle of brand ER oxycodone
from a proﬁle consistent with single entity opioids to one con-
sistent with opioid/acetaminophen combination products. In the
pre-formulation period, the highest rates of doctor-shopping for
brand ER oxycodone were observed among young adults and
rates of doctor-shopping decreased with increasing age. This age-
speciﬁc proﬁle was similar to that for other single-entity opioids,
including IR oxycodone SE, ER oxymorphone, ER morphine, and
IR hydromorphone. Post-reformulation, the age-speciﬁc doctor-
shopping proﬁle for brand ER oxycodone shifted and was similar
to that for opioid/acetaminophen combination products, such as
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R oxycodone/acetaminophen and hydrocodone/acetaminophen,
n which doctor-shopping rates were the highest for adults
5–54 year olds, and rates for middle-aged adults were twice
s high as those for young adults. The shift in the age-speciﬁc
octor-shopping proﬁle for brand ER oxycodone was due to a large
ecrease in doctor-shopping rate from before to after reformulation
or young adults (73% decrease), which was larger than decreases
or older adults. These results suggest that the reformulation of
rand ER oxycodone lowered its rate of non-medical use, particu-
arly non-oral abuse.
The pre- versus post-reformulation change in doctor-shopping
ates with increasing number of prescribers and/or pharmacies
or the threshold of doctor-shopping showed that the magnitude
f the decrease in doctor-shopping increased as the deﬁnition
f doctor-shopping increased in speciﬁcity with more selective
riteria (more prescribers and/or pharmacies). We  surmise that
ncreasing the threshold of the doctor-shopping criteria eliminates
egitimate pain patients who may  utilize multiple prescribers or
harmacies for justiﬁable reasons. In this report, relatively sensi-
ive and less speciﬁc criteria (2+ prescribers and 3+ pharmacies)
rovided a conservative estimate of changes in doctor-shopping
ates after reformulation, which possibly underestimates the effect
f the reformulation on the demand of brand ER oxycodone for
iversion through doctor-shopping. Once a threshold of four pre-
cribers or pharmacies was reached, the magnitude of pre-post
ecrease in doctor-shopping stabilized. We  infer that the use of
our or more prescription sources is more likely to deﬁne an actual
octor-shopper who is seeking to divert excess opioid.
In this analysis, the count of unique prescribers and pharma-
ies required only one day of overlap of prescriptions. This is a
ow threshold and could capture patients who ﬁlled a prescription
rom a different prescriber just as a prescription from another pre-
criber ended, or ﬁlled a prescription from the same prescriber at
 different pharmacy on the day the previous prescription ended.
he low threshold of one-day overlap is somewhat offset by the
equirement of at least 2 prescribers ﬁlled by at least three phar-
acies, with the multiple pharmacies contributing substantially
o the discriminant validity (Cepeda et al., 2012, 2013). It is likely
hat increasing the speciﬁcity of the doctor-shopping deﬁnition by
equiring an increase in the days of prescription overlap would
esult in larger declines in doctor-shopping for brand ER oxycodone
imilar to the increasing declines for higher numbers of pharmacies
nd prescribers for the deﬁnition of doctor-shopping.
A limitation is that the IMS  LRx database covers only around
wo-thirds rather than all retail prescriptions. As a result, numbers
f overlap events and counts of numbers of prescribers and phar-
acies may  be underestimated. Any underestimation of counts of
octor-shopping events is expected to occur similarly across drug
roducts and would be unlikely to bias ﬁndings in this report. An
dditional limitation is that some individuals might be identiﬁed
s doctor-shoppers for other opioids in addition to brand ER oxy-
odone, which would violate the assumption of independence of
bservations. To the extent to which this occurs, there would be
ittle impact on point estimates of ratio of relative risks, but stan-
ard errors would be underestimated somewhat. These limitations
re offset by particular advantages that provide support for the
onclusions. The data are national in scale, include other extended-
elease, immediate-release single-entity and immediate-release
ombination opioid products as comparators, and encompasses
ufﬁcient events to provide adequate statistical power for brand
R oxycodone doctor-shopping outcomes. In addition, it covers a
epresentative sample of the general population of those who  are
rescribed opioids, not just abusers or non-abusing pain patients.
he scale of the IMS  LRx dataset (covering >150 million patients
nd 65% of retail prescriptions in the U.S.) is generalizable to the
.S. population. Moreover, data generated by tracking prescriptionependence 165 (2016) 221–228 227
records of pharmacies where they are dispensed do not suffer from
limitations inherent in data generated through self-report (e.g.,
reporter bias or inaccurate reporting of speciﬁc opioid products).
Opioid analgesics are important pain management medications
for prescribers treating millions of legitimate patients in the U.S.
each year. A public health concern stems from the premise that
prescribers/pharmacies are providing an opportunity for illegiti-
mate use through doctor-shopping. The results in this report show
that the reformulation of a brand ER oxycodone product leads to
a meaningful decrease in this practice, particularly among young
adults, who represent a high risk age group for diversion and abuse.
The rate of brand ER oxycodone doctor-shopping decreased
substantially after its reformulation. Greater speciﬁcity of the def-
inition of doctor-shopping resulted in larger declines in rates
of doctor-shopping: the largest doctor-shopping reductions were
among youth, payments paid by cash and those involving 80 mg
tablets, consistent with a decreased demand for the reformulation
for diversion. Further, increasing the threshold for doctor-shopping
to require a higher number of prescribers and/or pharmacies during
periods of prescription overlap also resulted in a larger magnitude
of pre-post decrease in doctor-shopping. Other factors did appear
to have an impact on doctor-shopping for opioids in general as
indicated by the decline in doctor-shopping for several of the opi-
oid comparators but increases in others (eg,  66% increase for ER
oxymorphone); however, there was  a more pronounced effect for
brand ER oxycodone over and above the effect for other opioids.
These ﬁndings indicate that effective abuse-deterrent formulations
could be an important component of a multi-pronged approach to
reduce prescription opioid diversion and abuse.
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